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TRPV1 enhances the afferent 
response to P2X receptor activation 
in the mouse urinary bladder
Luke Grundy1,5, Donna M. Daly2, Christopher Chapple3, David Grundy4 & Russ Chess-Williams1
Both TRPV1 and P2X receptors present on bladder sensory nerve fibres have been implicated in 
mechanosensation during bladder filling. The aim of this study was to determine possible interactions 
between these receptors in modulating afferent nerve activity. In wildtype (TRPV1+/+) and TRPV1 
knockout (TRPV1−/−) mice, bladder afferent nerve activity, intravesical pressure, and luminal ATP 
and acetylcholine levels were determined and also intracellular calcium responses of dissociated 
pelvic DRG neurones and primary mouse urothelial cells (PMUCs). Bladder afferent nerve responses 
to the purinergic agonist αβMethylene-ATP were depressed in TRPV1−/− mice (p ≤ 0.001) and also 
in TRPV1+/+ mice treated with the TRPV1-antagonist capsazepine (10 µM; p ≤ 0.001). These effects 
were independent of changes in bladder compliance or contractility. Responses of DRG neuron to 
αβMethylene-ATP (30 µM) were unchanged in the TRPV1−/− mice, but the proportion of responsive 
neurones was reduced (p ≤ 0.01). Although the TRPV1 agonist capsaicin (1 µM) did not evoke 
intracellular responses in PMUCs from TRPV1+/+ mice, luminal ATP levels were reduced in the TRPV1−/− 
mice (p ≤ 0.001) compared to wildtype. TRPV1 modulates P2X mediated afferent responses and 
provides a mechanistic basis for the decrease in sensory symptoms observed following resiniferatoxin 
and capsaicin treatment for lower urinary tract symptoms.
As the bladder fills, the degree of distension is detected by mechanosensitive ion channels located either on sen-
sory nerve terminals or on the specialised epithelial lining of the bladder, the urothelium. This evokes an afferent 
signal that is conveyed to the CNS via the dorsal root ganglia. Initially this signal lies below the level of conscious-
ness, supplying the autonomic reflexes responsible for controlled bladder filling. As bladder volume increases, 
however, a sensation of fullness and a desire to void is perceived. In continent individuals this desire can be 
deferred until it is convenient to empty the bladder, however in patients with lower urinary tract conditions such 
as overactive bladder syndrome (OAB), bladder pain syndrome (BPS) or interstitial cystitis (IC), this sensation is 
difficult to defer, occurs when the bladder is not yet full and can even be accompanied by pain (BPS/IC) suggest-
ing that a defect in the ability of the bladder to detect filling may underlie these conditions.
Sensory innervation from the bladder is conveyed by myelinated low threshold Aδ fibres and unmyelinated 
high threshold C fibres carried in the pelvic, hypogastric and pudendal afferent nerves1. However, the complex 
mechanisms which determine how the afferent nerves detect bladder filling remain poorly understood, limiting 
the development of effective treatments for these bladder sensory defects.
There is compelling evidence that purinergic receptors play an active role in mechanosensation of the bladder 
in rodents. Firstly bladder projecting afferents express a number of P2X puringeric receptors, of which P2X2 and 
P2X3 are the main subtype. Secondly, ATP is able to activate pelvic nerve afferents arising from the rat urinary 
bladder and initiate bladder overactivity2,3. Thirdly, the P2X1 and P2X3 agonist, αβMethylene-ATP increases 
firing in both nociceptive and non-nociceptive populations of bladder afferents4. Finally, it has been shown that 
stretch or distension of the urothelium evokes the graded release of non-neuronal ATP5 which activates purin-
ergic receptors located on the afferent terminal to control afferent firing. Previous studies using P2X3 or P2X2/3 
null mice found profound attenuation of the afferent response to bladder filling, increased bladder capacity and 
decreased voiding frequency, supporting a role for ATP in bladder sensation5,6. Purinergic receptors are likely to 
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play a role in human urinary bladder physiology and pathophysiology, as P2X receptors are expressed in bladder 
smooth muscle7 and have been shown to mediate a non-adrenergic non-cholinergic component of contraction 
from patients with idiopathic detrusor instability8. P2X receptors have also been identified in myofibroblasts, 
urothelium, and sub-urothelial nerve fibres of human bladders9–11.
The transient receptor potential (TRP)V1 receptor is a member of the TRP superfamily, activated by noxious 
heat ≥ 43 °C, pH ≤ 6.0, and the vanilloids capsaicin and resiniferatoxin. TRPV1 is mostly confined to unmyeli-
nated, small diameter primary afferent fibres and has been consistently implicated in nociception, and inflamma-
tory pain12,13. In the urinary tract, TRPV1 is predominantly expressed on primary sensory afferent nerve fibres, 
whilst contradictory evidence both support and negate a functional role for TRPV1 in the urothelium14–20.
There is evidence to suggest that the TRPV1 receptor contributes to afferent nerve responses during bladder 
filling. TRPV1 knockout (TRPV1−/−) mice have reduced afferent responses to bladder distension, reduced reflex 
bladder activity and increased bladder capacity21,22. Moreover, application of capsaicin or RTX causes activation 
of bladder sensory nerves and increased reflex activity21,23, while systemic administration of a TRPV1 antagonist 
increases micturition threshold volume and decreases bladder contraction amplitude24. Previous studies have also 
shown that in experimental models of cystitis, genetic deletion or pharmacological blockade of TRPV1 prevents 
bladder hyperactivity25–27. However, TRPV1 is not considered to be a mechanically gated ion channel and thus the 
mechanism by which it is able to alter bladder sensitivity to filling remains unclear.
Previous clinical studies have shown that P2X3 immunoreactivity is significantly reduced in patients who 
respond positively to intravesical RTX therapy suggesting TRPV1 and P2X3 receptor expression may be cou-
pled28. Moreover, in cultures of human urothelial cells TRPV1 was identified at both mRNA and protein level 
and stimulation led to ATP release20, consistent with earlier studies in rodents22,29. Such studies implicate the 
urothelium in bladder sensory signalling, which we expanded upon here, in order to better understand the role of 
TRPV1 in modulating purinergic evoked bladder afferent activity in the mouse.
Results
Afferent nerve activity. Addition of αβMe-ATP (300 nM–100 µM) produced concentration-related 
increases in afferent nerve activity and intravesical pressure, indicating detrusor contraction (Fig. 1a,b,c). The 
afferent response was characterised by an initial rapid component followed by a period of more sustained firing 
before returning to baseline over 2–3 minutes. Application of αβMe-ATP (30 µM) initiated a pronounced det-
rusor contraction (Fig. 1d). The maximal firing and time course profiles in response to repeated application of 
αβMe-ATP were reproducible (Fig. 1e,f) (p ≥ 0.05, n = 9).
The afferent response to αβMe-ATP was significantly attenuated in TRPV1−/− mice compared to TRPV1+/+ 
control mice (p ≤ 0.0001, n = 9) (Fig. 2a). In order to examine this interaction further, the responses to αβMe-ATP 
in TRPV1+/+ mice were also examined in the absence and presence of the TRPV1 receptor antagonist capsaze-
pine (Fig. 2b,e). Capsazepine (10 µM) had no effect on bladder pressure or baseline afferent firing but significantly 
attenuated the response to αβMe-ATP (p ≤ 0.0001, n = 9) similar to that seen in TRPV1−/− mice (p < 0.05, n = 9) 
(Fig. 2b,c,d). Moreover, the time taken to reach maximal afferent firing was delayed in preparations from the 
TRPV1−/− mouse or following application of capsazepine (18 ± 3.2 s vs 64.4 ± 10.4 s and 51.1 ± 11.6 s respectively 
p < 0.05 for both changes, n = 9, Fig. 2e).
To determine if the decreased response to αβMe-ATP was due to a general change in neuronal excitability 
in the TRPV1−/− mice, peak afferent nerve responses to the nicotinic agonist DMPP was examined (Fig. 3a). In 
contrast to αβMe-ATP, DMPP had a similar effect in TRPV1+/+ and TRPV1−/− mice (139.1 ± 46.1imp s−1 n = 12 
and 157.2 ± 52.3imp s−1 respectively, n = 7, p ≥ 0.05).
The afferent nerve response to αβMe-ATP occurred concurrent with a moderate contraction of the detru-
sor smooth muscle. It is possible therefore that the changes in afferent nerve firing in the TRPV1−/− mice was 
secondary to altered detrusor muscle activity. However, this would appear not to be the case since there was 
no significant difference in αβMe-ATP induced bladder contraction between preparations from TRPV1+/+ and 
TRPV1−/− mice despite markedly different afferent firing profiles. Furthermore capsazepine (10 µM) failed to alter 
contractile responses to αβMe-ATP (p ≥ 0.05, n = 4) (Fig. 3b). Bladder compliance was assessed by the pressure/
volume relationship during distention. Compliance was also unaffected by the loss of functional TRPV1 receptors 
(Fig. 3c). To further examine the potential link between afferent firing and contractile activity the response to 
αβMe-ATP was compared under calcium free conditions. Removal of calcium completely abolished αβMe-ATP 
induced contraction (Fig. 3f). However, a robust afferent response to αβMe-ATP was maintained in calcium 
free conditions (Fig. 3d,e,f). Moreover, application of capsazepine still attenuated the afferent and peak afferent 
response to αβMe-ATP in calcium-free buffer (Fig. 3d,e,f; 86.6 ± 16.3imp−s Vs 53.6 ± 10.8imp−s, (p < 0.05, n = 7).
Responses in the DRG. A proportion of DRG neurons responded to αβMe-ATP with an increase in 
intracellular calcium (Fig. 4a). A subset of DRG neurons from WT mice responded to capsaicin (around 60% 
Fig. 4b), however, as expected, DRG neurons from TRPV1−/− failed to exhibit responses to capsaicin. There was 
no significant difference in maximal αβMe-ATP (30 µM) induced calcium rise in DRG neurons (24.4 ± 2.4% Vs 
28.1 ± 3.2%) from TRPV1+/+ and TRPV1−/− mice respectively (p ≥ 0.05, N = 12, n = 80) (Fig. 4c). However, the 
percentage of DRG neurons responding to αβMe-ATP was significantly lower in the TRPV1−/− mice compared 
to TRPV1+/+ (fig. 4d) (59.4 ± 4.9 Vs 36.3 ± 4.1%, p ≤ 0.01, N = 12).
Primary mouse urothelial cells. In order to examine how the urothelium might contribute to 
purinergic-TRPV1 signalling, experiments were performed with PMUCs and compared with isolated pelvic 
DRG neurons. mRNA for the TRPV1 receptor was expressed in both PMUCs and DRGs (Fig. 5a). However, the 
levels of expression were significantly greater in DRG neurons than PMUCs (p ≤ 0.01, n = 3). PMUCs responded 
to the purinergic agonist ATP with an increase in intracellular calcium in a concentration-dependent manner 
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(Fig. 5b) with pEC50 values of 3.49 ± 0.77 µM and 4.2 ± 0.74 µM in TRPV1+/+ and TRPV1−/− respectively (N = 6, 
n = 360, 470). There was no significant difference in the sensitivity to ATP between PMUC from TRPV1+/+ and 
TRPV1−/− animals. Interestingly direct application of capsaicin to PMUC failed to elicit a rise in intracellular 
calcium (fig. 5c) (n = 3, n = 57) despite robust responses to ATP.
Mediator release. ATP was released from the urothelium both at rest and in response to distension (Fig. 5d). 
In the present study we found that the stretch evoked ATP release observed in TRPV1+/+ mice (4.1 ± 0.9 Vs 
14.4 ± 3 nM p ≤ 0.01 n = 6) was absent in the TRPV1−/− mice. In contrast the release of acetylcholine at rest or 
during bladder distension was unchanged in TRPV1−/− mice (p ≥ 0.05 compared to TRPV1+/+ basal and stretch, 
n = 6) (Fig. 5e).
Discussion
A number of previous studies have shown that P2X3 sensitive afferent nerves are essential for normal bladder 
function and that purinergic responses in sensory neurons are largely mediated by P2X2, P2X3 and P2X2/3 
receptors5,6. Moreover, P2X receptors have been shown to co-localise on afferents expressing TRPV130,31, and 
co-immunoprecipitation studies have demonstrated a physical association of TRPV1 and P2X3 receptors in the 
DRG32. P2X3 immunoreactivity on bladder projecting neurons is significantly increased in patients with neuro-
genic detrusor overactivity33 and is significantly reduced in those patients who responded positively to intraves-
ical application of the TRPV1 agonist, resiniferatoxin, which causes receptor desensitisation, further suggesting 
there may also be a functional association between the TRPV1 and P2X3 receptors on bladder afferent neurons 
Figure 1. Bladder afferent nerves respond to αβMe-ATP. (a) Experimental trace of afferent nerve activity 
in response to increasing concentrations of αβMe-ATP applied for 60 s before washout; (b) concentration-
response curve of afferent nerve activity to αβMe-ATP; (c) concentration-response curve of intravesical 
pressure (contraction) to αβMe-ATP; (d) afferent nerve and intravesical pressure responses to repeat 
applications of αβMe-ATP (30 µM); (e) afferent nerve time course response to repeated applications of αβMe-
ATP (30 µM) applied for 60 s before washout; (f) peak afferent firing in response to repeat application of αβMe-
ATP (30 µM). Data shown are mean ± SEM (n = 9).
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innervating the bladder33. The results presented in this study provide the first direct evidence that the TRPV1 
receptor is able to influence bladder afferent responses to P2X stimulation, a process considered essential to 
mechanosensation during bladder filling.
αβMe-ATP is a non-selective agonist which activates P2X1 and p2X3 receptor subtypes. Previous studies have 
provided compelling evidence that P2X1 receptors located on the smooth muscle mediate bladder contraction34 
and P2X3 receptors located on the afferent nerves play a role in mechanosensation4,6. Bladders from wildtype 
mice responded to the application of αβMe-ATP with a transient bladder contraction and a profound afferent 
response. In calcium free Krebs, bladder contractions were lost but nerve firing persisted, albeit diminished. This 
suggests that the receptors responsible for these two components are distinct, and, given the body of evidence 
in the literature is seems likely that P2X1 receptors on the muscle mediate the contractile response while P2X3 
receptors34 at the nerve terminal drive the direct nerve response. Membrane bound ionotropic P2X1 and P2X3 
receptors, when bound by ATP, mediate non-selective cation influx of Na+, and Ca2+, and the efflux of K+ across 
the cell membrane under physiological ionic distribution to initiate cell depolarisation35. The degree of afferent 
firing that is maintained in Ca2+ free buffer in our experiments is likely a consequence of direct Na+ induced 
membrane depolarisation. Whilst P2X1 receptor mediated influx of both Na+ and Ca2+ influx in smooth muscle 
cells creates an excitatory junction potential, it is the subsequent opening of voltage gated calcium channels and 
calcium induced calcium release from intracellular stores which create the concentrations of intracellular calcium 
necessary for smooth muscle contraction36. Afferent responses to αβMe-ATP were also tested in the presence of 
the L-type calcium channel blocker nifedipine. Nifedipine significantly attenuated bladder muscle contraction 
with no effect on afferent firing (unpublished data), further supporting differential dependence of voltage gated 
calcium channels for muscle contraction and afferent firing in response to P2X receptor activation.
Figure 2. TRPV1 has a role in P2X mediated bladder afferent signaling. (a) Afferent nerve response to αβMe-
ATP(30 µM), applied for 60 s, in bladder preparations from TRPV1+/+ and TRPV1−/− mice. (b) Afferent nerve 
response to repeated applications of αβMe-ATP for 60 s in bladders from TRPV1+/+ mice in the presence 
and absence of capsazepine; Data shown are mean ± SEM, two-way ANOVA with Tukeys post-hoc test 
****p ≤ 0.0001 (n = 9). (c) Afferent nerve and intravesical pressure responses to repeat applications of αβMe-
ATP in TRPV1+/+ mice prior to and following incubation with capsazepine. (d) Peak afferent nerve responses 
to αβMe-ATP (30 µM) in TRPV1+/+ mice in the presence and absence of capsazepine, and TRPV1−/− mice; 
(e) Time taken to reach maximum afferent nerve impulse frequency in response to αβMe-ATP (30 µM). Data 
shown are mean ± SEM, one-way ANOVA with Tukeys post-hoc test *p < 0.05, **p ≤ 0.01 (n = 9).
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Loss of TRPV1 reduced the bladder afferent response to αβMe-ATP application. It is possible that P2XR 
expression on bladder afferent endings is altered in the TRPV1−/−, thereby affecting the sensitivity to αβMe-ATP. 
However, the effect of TRPV1 deletion was replicated by the acute treatment with capsazepine, indicating that 
the attenuated response to αβMe-ATP is unlikely due to a reduction in P2X receptor expression. The similar 
attenuation observed in the TRPV1−/− and capsazepine treated wildtype mice is also consistent with capsaz-
epine’s pharmacological antagonism of the TRPV1 receptor rather than as a consequence of any non-specific 
or smooth muscle actions. Interestingly, knockout or pharmacological blockade of the TRPV1 receptor had no 
effect on detrusor muscle contraction stimulated by αβMe-ATP suggesting that the interaction was at the level of 
the afferent nerve or urothelium rather than secondary to changes in muscle tone. The effect of capsazepine on 
afferent firing persists after contractile responses are attenuated in calcium free conditions, again ruling out any 
effect on bladder contractility. These results are supported by a previous study from our laboratory showing that 
mechanosensitive responses to ramp distension are significantly attenuated by removal or block of TRPV1 with 
no concurrent effect on bladder compliance during ramp distension21.
TRP channels have been recently shown to modulate the sensitivity of other ion channels37 through extensive 
phosphorylation of intracellular signalling molecules, which in the case of TRPV1 and P2X3/P2X2/3 have been 
shown to be regulated by the phosphoinositides PiP2 and PiP3 in peripheral neurons38,39. Thus it is possible that 
removal or blockade of the TRPV1 receptor reduces the sensitivity of P2X3 receptors by alterations to its intra-
cellular signalling cascade.
A previous study into the role of TRPV1 in intestinal mechanosensitivity suggested that loss of TRPV1 func-
tion leads to an overall reduction in the pre-tuning of the afferents, thereby reducing excitability40. In order to test 
whether this would explain the phenomenon observed in our study we examined the effect of TRPV1 knockout 
on the bladder afferent responses to a nicotinic agonist, DMPP, as nicotinic agonists have previously been shown 
to stimulate capsaicin sensitive bladder afferents41. The rationale behind this was to stimulate the bladder by a 
non-purinergic mechanism in order to assess whether the loss of TRPV1 caused a reduction in nerve sensitivity 
to both agonists or if the response was specific for αβMeATP. We found no significant difference in the response 
to DMPP between the wild-type and knock-out mice suggesting that loss of TRPV1 did not result in an overall 
Figure 3. TRPV1 is coupled to P2X mediated afferent firing. (a) Peak afferent nerve responses to bath applied 
DMPP (100 µM) in TRPV1+/+ and TRPV1−/− mice. (b) Bladder contraction responses to αβMe-ATP (30 µM) 
in the presence (white bars) and absence (black bars) of capsazepine in TRPV1+/+ and TRPV1−/− mice.  
(c) pressure/volume relationship within the bladder when distended with saline in TRPV1+/+ and TRPV1−/− 
mice. (d) Afferent nerve response to repeated applications of αβMe-ATP for 60 s in calcium free modified 
krebs solution with, or without, capsazepine (10 µM); Data shown are mean ± SEM, two-way ANOVA with 
Bonferroni post-test ****p ≤ 0.0001 (n = 7). (e) Afferent response to αβMe-ATP (30 µM) in calcium free 
modified Krebs solution with or without capsazepine. Data shown are mean ± SEM, one-way ANOVA with 
Tukeys post-hoc test ns p ≥ 0.05, *p < 0.05 (n = 7).
www.nature.com/scientificreports/
6SCientiFiC REPORts |  (2018) 8:197  | DOI:10.1038/s41598-017-18136-w
loss of bladder sensitivity, but that inhibited P2X receptor responses in the TRPV1 knockout is due to a specific 
interaction between the TRPV1 and P2X3 receptors.
Dorsal root ganglia. To investigate this relationship in the absence of other potentially confounding factor in 
the bladder wall, responses to αβMeATP were determined in primary cultures of DRG neurons from lumbosacral 
(L6/S2) and thoracolumbar (T11/L2) regions from TRPV1+/+ and TRPV1−/− mice. DRG neurons from TRPV1+/+ 
responded to αβMe-ATP with an increase in intracellular calcium with similar proportions to those reported by 
others42. We found that the magnitude of the calcium signal was not different between neurons from TRPV1+/+ 
and TRPV1−/− mice. The opening of P2X receptors following αβMe-ATP binding permits the influx of Na+, as well 
as Ca2+ ions. Membrane depolarization of sensory neurons is dependent on Na+ influx, and results in the opening 
of voltage-gated calcium channels to act as a second messenger of electric signalling36. Sensory neuronal signalling 
through calcium influx is further amplified by calcium-induced calcium release from intracellular stores which is 
much larger than the initial calcium influx through P2X receptor ion channels. Thus, it is likely that any difference 
in P2X-receptor excitability between TRPV1−/− and TRPV1+/+ mice is masked by the much larger calcium signals 
associated with the opening of calcium channels. The proportion of DRG neurons responding to αβMe-ATP was 
significantly reduced in the TRPV1−/− neurons compared to the wildtypes. In a previous study, Kiyatkin et al. 
found that 30% of DRG neurons exhibit functional responses to both αβMe-ATP and capsaicin confirming that a 
subpopulation of neurons in the DRG co-express functional TRPV1 and P2X3 receptors43. We found the number 
of responsive DRG neurons in the TRPV1−/− mice was reduced by about 25%, which likely represents the propor-
tion of co-expressing cells in the wild type animals whose absence in the knockout animals would account for the 
attenuated ex-vivo afferent firing in response to αβMe-ATP. Since a similar attenuation was seen following the acute 
(30 min) treatment with capsazepine it would imply that P2X receptor expression is unchanged in the knockout but 
sensitivity to ligand is blunted. Together this data suggests that TRPV1 interacts with the P2X3 receptor to modify 
its sensitivity to agonist stimulation rather than the loss of TRPV1 alters P2X3 receptor expression and further 
experiments are planned to determine if this is indeed the case. The exact mechanisms involved in this interaction 
and down-stream signalling pathway still remain to be determined.
Figure 4. The role of TRPV1 in DRG responses to P2X agonists. (a) Individual DRG neurons respond to 
αβMe-ATP (30 µM), applied for 60 s before washout, with an increase in intracellular calcium; (b) mean 
response of DRGs to αβMe-ATP (30 µM) from TRPV1+/+ and TRPV1−/− mice; (c) peak intracellular calcium 
response of DRGs to αβMe-ATP (30 µM) from TRPV1+/+ and TRPV1−/− mice; (d) percentage of DRG neurons 
responding (black bar) and non-responding (grey bar) to αβMe-ATP (30 µM); Data shown are mean ± SEM, 
two-tailed unpaired t-test ns p ≥ 0.05, **p ≤ 0.01 (n = 12, N = 80).
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The urothelium. The bladder urothelium plays a key role in modulating the excitability of bladder afferent 
nerves. This is achieved by the non-neuronal release of inhibitory (such as NO) and excitatory (such as ATP) 
mediators. In this study, we examined whether the absence of TRPV1 also influenced the ability of the urothelium 
to respond to purinergic receptor stimulation or alter transmitter release. In concordance with a number of previ-
ous studies, we found no evidence that capsaicin caused a calcium response from urothelial cells14,15,18 suggesting 
that TRPV1 may not be functionally coupled to calcium entry or release from intracellular stores in the mouse 
urothelium, at least under baseline conditions. Paradoxically, however, ATP release from the bladder was atten-
uated in the TRPV1−/− mouse, an effect which has previously been reported using isolated rat urothelial cells22.
As such, the role of TRPV1 in the urothelium remains controversial, and the detection of a functional TRPV1 
receptor from a range of species, including human, appears to be dependent on the specific experimental proce-
dures used, and perhaps an over reliance on immunocytochemistry in the absence of confirmatory assays14–20.
In the present study TRPV1 mRNA was identified in the urothelium, albeit in low levels, suggesting that 
TRPV1 might be expressed in urothelial cells despite the failure of capsaicin to evoke a response. This suggests 
that the levels of TRPV1 mRNA translation may be insufficient to elicit a calcium response, yet high enough to 
affect ATP release. Immunohistochemical localisation of TRPV1 in the urothelium has been questioned, citing 
a lack of knockout studies and relevant controls44. Genetic deletion of TRPV1 can lead to compensatory changes 
that attenuate ATP release. Birder et al. (2002) showed that capacitance of the urothelium was blunted in the 
TRPV1−/− mouse suggesting that urothelial trafficking mechanisms might be disrupted following deletion of 
TRPV122. Importantly, however there was no difference in the sensitivity of PMUCs to ATP as indicated by 
similar pEC50s suggesting that the interaction between TRPV1 and purinergic receptors observed in the afferent 
recordings are unlikely to be due to a mechanism involving the urothelium.
In contrast to ATP, acetylcholine release was unaffected by the loss of TRPV1. This was surprising since sev-
eral previous studies have shown that ATP mediates a positive feedback mechanism on ACh outflow from the 
urothelium45,46. The fact that ATP release was changed by the loss of TRPV1 but that ACh release was not suggests 
that this feedback mechanism was uncoupled. This may be as a direct result of the differential release mechanism 
for the two mediators (ie ATP is released vesicularly in a graded manner, whereas ACh is released independent of 
vesical trafficking in an all-or-nothing manner)47 or a developmental compensation aimed at maintaining control 
over micturition. However, until further studies are conducted to understand how these two transmitters are 
coupled interpreting this data can only be speculative.
Concluding remarks. The TRPV1 receptor may have two synergistic roles in mediating bladder mechano-
sensitivity. A modulatory role in regulating the release of ATP from the urothelium, coupled with a decrease in 
afferent nerve sensitivity to ATP could combine to result in the deficit in mechanosensitivity observed during 
bladder distension21. Importantly it has been shown that the relative density of suburothelial P2X3 and TRPV1 
immunoreactive nerves increases in disease28,33 and is significantly reduced following successful treatment with 
intravesical instillation of resiniferatoxin or capsaicin to cause receptor desensitization. This pathway, therefore, 
may contribute a larger proportion of the mechanosensory response to distension during pathophysiological 
conditions. The present results provide a mechanistic basis for the decrease in sensory symptoms seen following 
Figure 5. The effect of TRPV1 on urothelial responses to P2X stimulation. (a) Relative expression of TRPV1 in 
PMUC and pelvic DRG neurons;; Data are mean ± SEM, two tailed un-paired t-test ***p ≤ 0.001 (n = 3); (b) 
normalised concentration response curve of PMUC intracellular calcium to ATP in TRPV1+/+ and TRPV1−/− 
mice (n = 6); (c) change in intracellular calcium levels of PMUCs to capsaicin and ATP; (d) intraluminal ATP 
and (e) acetylcholine release from TRPV1+/+ and TRPV1−/− mouse bladders; Data are mean ± SEM, one-way 
ANOVA with Tukeys post-hoc test **p ≤ 0.01, ***p ≤ 0.001 (n = 6).
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resiniferatoxin and capsaicin treatment for lower urinary tract symptoms48,49, although the relative contribution 
of the urothelium and the sub-urothelial afferent nerves remains unknown.
Methods
Animals. All experiments were performed in accordance with the University of Sheffield’s Animal Care 
Committee under a project license issued by the UK Animals (Scientific Procedures) Act 1986. TRPV1 wildytpe 
(TRPV1+/+) and TRPV1 Knockout (TRPV1−/−) mice with a genetic background of C57/BL6 were obtained from 
GlaxoSmithKline (Harlow, UK). Trans-membrane domains 2–4 of the mouse VR1 gene (i.e. DNA encoding 
amino acids 460–555) were replaced by the neo gene50. Mating pairs of TRPV1−/− and TRPV1+/+ N1F1 litter-
mates were used to generate separate colonies of TRPV1+/+ and TRPV1−/− mice at the University of Sheffield. In 
the course of the study, genotyping was periodically performed to confirm the absence of the TRPV1 gene in the 
TRPV1−/− mice. There were no overt differences in feeding behaviour, litter size, growth rate and body weight 
between TRPV1−/− and TRPV1+/+ groups.
16–18 week-old male TRPV1−/− and TRPV1+/+ animals were used in this study. Maintenance and killing of 
the animals followed principles of good laboratory practice in compliance with UK national laws and regulations. 
The mice were killed humanely by cervical dislocation.
Afferent nerve recording. Nerve recording was conducted using an in vitro model previously described12. 
The whole pelvic region was dissected and placed in a recording chamber (30 mls), continually perfused with 
gassed (95% O2, 5% CO2) Krebs-bicarbonate solution (composition in mmol/L: NaCl 118.4, NaHCO3 24.9, CaCl2 
1.9, MgSO4 1.2, KCl 4.7, KH2PO4 1.2, glucose 11.7) at 35 °C. The urethra and dome were cannulated to enable 
recording of intravesical pressure and enable evacuation of fluid. Pelvic and hypogastric nerves were dissected 
into fine multiunit branches, and afferent activity was recorded by a neurolog headstage (NL100, Digitimer Ltd, 
UK), amplified, filtered (NL215, band pass 300–4000 Hz) and captured by a computer via a power 1401 interface 
and Spike 2 software (version 7, CED, UK).
Isolation of mouse dorsal root ganglion (DRG) neurones. DRG’s from pelvic (L6-S1) and hypogastric 
(L1-L2) regions of the mouse spinal cord were isolated and incubated in HBSS (pH 7.4) containing collagenase 
(4 mg/ml), and dispase (4.5 mg/ml), at 37 °C for 20 minutes. The collagenase/dispase solution was aspirated and 
replaced with Hanks balanced salt solution (HBSS) containing papain (2 mg/ml) for 20 minutes at 37 °C. The 
papain solution was aspirated, replaced with 500 µl DMEM F12 (Gibco) and cells were dissociated via tritura-
tion with a Pasteur pipette. Cells were plated onto matrigel coated coverslips (corning) and left for 2 hrs before 
flooding with DMEM containing 10% FBS and Penstrep (100 IU/ml of penicillin and 100 ug/ml of streptomycin) 
(Sigma).
Isolation of mouse urothelial cells. Bladders from TRPV1−/− and TRPV1+/+ mice were dissected, pinned 
urothelial side up and incubated with MEM media containing 2.5 mg/ml dispase (2–3 hours at 21 °C). Cells were 
collected by gentle scraping and dissociated in 0.025% trypsin EDTA at 37 °C (10 minutes) and re-suspended in 
keratinocyte serum free media (KSFM) before plating overnight onto collagen (IV) coated coverslips.
Calcium imaging of cultured urothelial and DRG neurones. Cultured DRG neurones and urothelial 
cells (20–24 hours) were loaded with 2 μM fura-2-acetoxymethyl ester (fura-2AM) for 30 minutes at 37 °C and 
washed (Hepes buffer: Hepes 10 mM, NaCl 135 mM, KCl 5 mM, glucose 10 mM, CaCl22 mM and MgCl2 1 mM, 
pH 7.4) for 1 hr prior to imaging. Cells were stimulated with either ATP, αβMethylene ATP, or capsaicin for 
3–5 minutes and changes in intracellular calcium [Ca2+]i, were monitored in real-time. Ionomycin (Sigma) (5 µM) 
was applied as a positive control in DRG experiments. Results are expressed either as relative fluorescence (RF) 
or normalised to percentage of maximum ionomycin-induced calcium influx to overcome intra-experimental 
variability. [Ca2+]i is represented as the ratio between the fluorescence signal at 340/380 nm. Numbers are quoted 
as: N = number of mice and n = number of cells.
Experimental protocols. In nerve recording experiments, the preparation was allowed an equilibration 
period of 30 min before any experimental protocol commenced. Control bladder distensions were always carried 
out using isotonic saline (NaCl, 0.9%) at a rate of 100 µl min−1 to a maximum pressure of 40 mmHg; at this pressure 
the infusion pump was stopped and rapid evacuation of the fluid occurred by opening the two-way catheter in the 
dome. This was repeated several times at intervals of 10 min to assess the viability of the preparation and repro-
ducibility of the intravesical pressure and neuronal responses to distension. Following equilibration, bladders 
were partially filled (12 mmHg) with the outflow tap closed and left to equilibrate until bladder pressure and base-
line nerve activity were stable (approx. 45 mins). αβMethylene-ATP (30 µM) or dimethyl-4-phenylpiperazinium 
(DMPP) (100 µM) were applied to the bath by bolus dose and washed out with Krebs buffer after 60 seconds with 
the perfusion system. Krebs buffer was continually perfused for one hour to minimize receptor desensitisation 
before a second administration of experimental compound. In some experiments, capsazepine (CPZ) (10 µM), 
or vehicle control (0.01% DMSO) was perfused in the Krebs solution for the period prior to the second stimulus. 
Bladder contraction was measured as a change in intravesical pressure (mmHg) and latency was calculated as the 
time (in seconds) from drug application to maximal nerve firing.
Mediator release. Sequential filling (ramp distension) of a catheterised bladder (as described above) 
was performed (0.9% NaCl, to 40 mmHg). Intraluminal fluids were collected and the amount of ATP and 
Acetylcholine (ACh) in the samples was determined using the luciferin-luciferase ATP bioluminescent assay and 
the Amplex red ACh/ACh esterase assay kit (Molecular Probes).
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qPCR. mRNA from cultured urothelial cells and DRG neurones (20–24 hrs) was isolated (RNAeasy 
minikit, Qaigen) and cDNA was synthesised by reverse transcription using superscript III (Invitrogen) from 
mRNA following the manufacturers protocol. cDNA was amplified by PCR for 35 cycles with the follow-
ing primers and Sybr green fluorescence (Biorad). Primer sequence for the TRPV1 receptor was forward 5′ 
CAAGGCTCTATGATCGCAGG 3′ and reverse 5′GAGCAATGGTGTCGTTCTGC 3′. All samples were assayed 
in triplicate in the same plate. The relative amount of target mRNA was calculated by the 2−ΔΔCt method using 
β-actin as a housekeeping gene.
Data analysis and Statistics. Whole nerve multi-fibre afferent nerve activity was quantified using a Spike2 
software which counted number of action potentials crossing a pre-set threshold (Cambridge Electronic Design, 
Cambridge, UK).
For afferent nerve recording experiments, baseline activity was subtracted from stimulus induced response. 
Data are presented as means ± S.E.M. Statistical analysis was carried out using either a 1 or 2-way ANOVA 
and appropriate post-hoc test or a Student’s T-test, where appropriate. Tukey post-hoc test was used for 2-way 
ANOVA when n values for groups was the same, and Bonferroni for all other ANOVA, with significance con-
firmed at P < 0.05.
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